InMed Pharmaceuticals(INM)

VANCOUVER, British Columbia, CanadaPharmaceutical

Focus: InMed Pharmaceuticals is a public-stage biotech focused on cannabinoid-based therapeutics with a proprietary cannabinoid database platform. The company operates at small scale with $5M revenue and a single Phase 2 program.

Neurology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About InMed Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow InMed Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$5M

FY2025

Pipeline & Clinical Trials

INM-755

Epidermolysis Bullosa Simplex

PHASE_2

Clinical Trials (1)

NCT04908215INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa

Phase 2

Help build intelligence for InMed Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage cannabinoid platform with emerging clinical validation in rare skin diseases (INM-755 Phase 2 for Epidermolysis Bullosa Simplex)
High R&D intensity (70%) signals commitment to innovation and drug development over commercial optimization
Public company status provides liquidity and potential equity upside in an emerging therapeutic area

Watch Out For

Minimal revenue base ($5M) and significant operating losses ($7.7M in FY2025) create near-term funding and sustainability risk
Single-program pipeline (1 Phase 2 trial) with no Phase 3 or commercial products limits career stability and advancement runway
Zero active job openings at time of data collection suggests limited hiring and potential internal constraints

Generated by Claude from InMed Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

Revenue

$5M11%

R&D Spend

$3M(70%)14%

Net Income

-$8M

Cash

$7M

Source: SEC 10-K Filing